BioSpace News Archive

Kovina Therapeutics Inc. announced receipt of a Small Business Innovation Research (SBIR) one-year Phase I award from the National Institute of Allergy and Infectious Diseases (NIAID)/NIH to treat Human Papillomavirus (HPV) premalignant infections.

Antinuclear antibodies are a group of autoantibodies produced by an individual’s immune system when it fails to distinguish between self and foreign particles.

Rise in the need for apt treatment to patients during the medical emergencies globally is estimated to bolster the global ion-selective clinical lab analyzers market during the forecast period of 2021 to 2031.

Volastra Therapeutics , an oncology company focused on exploiting chromosomal instability to treat cancer, today announced it has been named as one of Fierce Biotech’s 2022 “Fierce 15,” designating it as one of the most promising early-stage biotechnology companies in the industry.

DNAnexus, Inc., the leading provider of cloud-based genomic and biomedical data access and companion analysis software, announced that it has been awarded a three-year contract by Our Future Health.

Astellas Pharma Inc. (TSE:4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”), Seagen Inc. (Nasdaq:SGEN) and Merck (NYSE: MRK) today announced results from the phase 1b/2 EV-103 clinical trial (also known as KEYNOTE-869) Cohort K investigating PADCEV® (enfortumab vedotin-ejfv) in combination with Merck’s anti-PD-1 therapy KEYTRUDA® (pembrolizumab) and PADCEV alone as first-line treatment in patients with unresectable locally advanced or metastatic urothelial cancer.

Seagen, Astellas and Merck Announce Results of Clinical Trial Investigating PADCEV ® (enfortumab vedotin-ejfv) with KEYTRUDA ® (pembrolizumab) and PADCEV as Monotherapy in First-Line Advanced Urothelial Cancer.

CurveBeam AI, Ltd announced its medical diagnostic software, OssView™, has received US Food and Drug Administration (FDA) Breakthrough Device Designation.

Hansa Biopharma, “Hansa” (NASDAQ Stockholm: HNSA), a pioneer in enzyme technology for rare immunological conditions, today announce the recommendation by the Scottish Medicines Consortium (SMC) for its first-in-class treatment Idefirix® in the desensitization of highly sensitized adult patients prior to kidney transplant from a deceased donor.

Olympus announced today it will distribute EndoClot® Polysaccharide Hemostatic Spray and EndoClot® Submucosal Injection Solution, two important products developed by EndoClot Plus, Inc.